Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1195

2.

Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J, Zhang L, Wang J, Cao X.

J Mol Med (Berl). 2003 Sep;81(9):585-96. Epub 2003 Aug 21.

PMID:
12937899
3.
4.

Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.

Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL.

J Immunol. 1999 Jul 15;163(2):699-707.

5.

Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.

Tüting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL Jr, Wagner SN, van der Bruggen P, Baar J, Lotze MT, Storkus WJ.

J Immunol. 1998 Feb 1;160(3):1139-47.

6.

Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell response in vitro and in vivo.

Cochlovius B, Linnebacher M, Zewe-Welschof M, Zöller M.

Int J Cancer. 1999 Nov 12;83(4):547-54.

7.

Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.

Okada N, Masunaga Y, Okada Y, Mizuguchi H, Iiyama S, Mori N, Sasaki A, Nakagawa S, Mayumi T, Hayakawa T, Fujita T, Yamamoto A.

Gene Ther. 2003 Oct;10(22):1891-902.

PMID:
14502218
9.

Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA.

J Immunol. 1996 Jan 15;156(2):700-10.

PMID:
8543823
10.

Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.

Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P.

Clin Cancer Res. 2006 Oct 1;12(19):5801-8.

12.

Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.

Xia DJ, Zhang WP, Zheng S, Wang J, Pan JP, Wang Q, Zhang LH, Hamada H, Cao X.

Gene Ther. 2002 May;9(9):592-601.

14.

Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo.

Wagner SN, Wagner C, Lührs P, Weimann TK, Kutil R, Goos M, Stingl G, Schneeberger A.

J Invest Dermatol. 2000 Dec;115(6):1082-7.

15.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
16.

Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.

Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, Jones CL, He LZ, Goldstein J, Wallace PK, Keler T, Endres MJ.

J Immunol. 2004 Mar 1;172(5):2845-52.

17.

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.

18.

Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.

Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, Gauldie J.

Cell Immunol. 1999 Dec 15;198(2):131-8.

PMID:
10648127
19.

Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells.

Prabakaran I, Menon C, Xu S, Gómez-Yafal A, Czerniecki BJ, Fraker DL.

Ann Surg Oncol. 2002 May;9(4):411-8.

PMID:
11986195
20.

Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.

Trevor KT, Cover C, Ruiz YW, Akporiaye ET, Hersh EM, Landais D, Taylor RR, King AD, Walters RE.

Cancer Immunol Immunother. 2004 Aug;53(8):705-14. Epub 2004 Mar 26.

PMID:
15048588

Supplemental Content

Support Center